EP1434881A4 - Verfahren zur diagnose von krebszusammensetzungen und verfahren zum screening auf krebsmodulatoren - Google Patents

Verfahren zur diagnose von krebszusammensetzungen und verfahren zum screening auf krebsmodulatoren

Info

Publication number
EP1434881A4
EP1434881A4 EP02766297A EP02766297A EP1434881A4 EP 1434881 A4 EP1434881 A4 EP 1434881A4 EP 02766297 A EP02766297 A EP 02766297A EP 02766297 A EP02766297 A EP 02766297A EP 1434881 A4 EP1434881 A4 EP 1434881A4
Authority
EP
European Patent Office
Prior art keywords
methods
cancer
modulators
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02766297A
Other languages
English (en)
French (fr)
Other versions
EP1434881A2 (de
Inventor
Daniel Afar
Natasha Aziz
Kurt C Gish
Peter A Hevezi
David H Mack
Keith E Wilson
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Priority to EP06007721A priority Critical patent/EP1721977A3/de
Publication of EP1434881A2 publication Critical patent/EP1434881A2/de
Publication of EP1434881A4 publication Critical patent/EP1434881A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57449Specifically defined cancers of ovaries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP02766297A 2001-09-17 2002-09-17 Verfahren zur diagnose von krebszusammensetzungen und verfahren zum screening auf krebsmodulatoren Withdrawn EP1434881A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06007721A EP1721977A3 (de) 2001-09-17 2002-09-17 Verfahren zur Krebsdiagnose, Zusammensetzungen und Screening-verfahren für Krebsmodulatoren

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US32346901P 2001-09-17 2001-09-17
US323469P 2001-09-17
US32388701P 2001-09-20 2001-09-20
US323887P 2001-09-20
US35066601P 2001-11-13 2001-11-13
US350666P 2001-11-13
US35514502P 2002-02-08 2002-02-08
US35525702P 2002-02-08 2002-02-08
US355257P 2002-02-08
US355145P 2002-02-08
US37224602P 2002-04-12 2002-04-12
US372246P 2002-04-12
PCT/US2002/029560 WO2003025138A2 (en) 2001-09-17 2002-09-17 Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP06007721A Division EP1721977A3 (de) 2001-09-17 2002-09-17 Verfahren zur Krebsdiagnose, Zusammensetzungen und Screening-verfahren für Krebsmodulatoren

Publications (2)

Publication Number Publication Date
EP1434881A2 EP1434881A2 (de) 2004-07-07
EP1434881A4 true EP1434881A4 (de) 2005-10-26

Family

ID=27559718

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02766297A Withdrawn EP1434881A4 (de) 2001-09-17 2002-09-17 Verfahren zur diagnose von krebszusammensetzungen und verfahren zum screening auf krebsmodulatoren

Country Status (5)

Country Link
EP (1) EP1434881A4 (de)
JP (1) JP2005518782A (de)
AU (1) AU2002330039A1 (de)
CA (1) CA2459219A1 (de)
WO (1) WO2003025138A2 (de)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6986201A (en) 2000-06-16 2002-01-02 Biogen Inc Renal regulatory elements and methods of use thereof
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
ATE382060T1 (de) 2001-06-01 2008-01-15 Biogen Idec Inc Moleküle und verfahren zur inhibierung der freisetzung von kim-1
AU2002330713A1 (en) * 2001-09-24 2003-04-07 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE364690T1 (de) 2001-11-09 2007-07-15 Proteologics Inc Posh nukleinsäure, polypeptide und darauf bezogene verfahren
CA2479732A1 (en) * 2002-03-19 2003-10-02 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003087408A2 (en) * 2002-04-05 2003-10-23 University Court Of The University Of Edinburgh Schizophrenia associated genes
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
WO2004001060A2 (en) 2002-06-20 2003-12-31 Bristol-Myers Squibb Company Identification and regulation of a g-protein coupled receptor, rai-3
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
EP1578762A4 (de) * 2002-11-12 2006-08-02 Wyeth Corp Neues, auf pthansprechendes gen
CN1835769B (zh) 2002-12-30 2011-06-29 比奥根艾迪克Ma公司 Kim-1拮抗剂及其在免疫系统调节中的应用
JP4462964B2 (ja) * 2003-03-10 2010-05-12 第一三共株式会社 癌特異的抗原を標的とした抗体
EP1615991A4 (de) 2003-04-03 2007-12-19 Bristol Myers Squibb Co Neue menschliche p2x7-spleissvariante hbmyp2x7v codierendes polynukleotid
EP1923401A3 (de) * 2003-04-14 2008-08-20 Novartis AG Genexpression in Zusammenhang mit Osteoblastendifferenzierung
EP1623230A2 (de) * 2003-05-05 2006-02-08 Bayer HealthCare AG Diagnostika und therapeutika für krankheiten, die mit gpr39 (g-protein coupled receptor gpr39) assoziiert sind
WO2005001049A2 (en) * 2003-06-06 2005-01-06 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2005066363A2 (en) * 2004-01-09 2005-07-21 Medigen Biotechnology Corporation Cancer specific gene ccndbp1
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
EP1721165B1 (de) * 2004-02-27 2010-03-03 Institut Curie Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1741792B1 (de) 2004-04-27 2010-11-03 Takeda Pharmaceutical Company Limited Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
EP1747467A1 (de) * 2004-05-11 2007-01-31 Bayer HealthCare AG Diagnostika und therapeutika für mit dipeptidyl-peptidase 6 (dpp6) assoziierten krankheiten
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
ZA200701183B (en) 2004-07-20 2008-05-28 Genentech Inc Inhibitors of angiopoietin-like 4 protein, combinations, an their use
ZA200701184B (en) 2004-07-20 2008-07-30 Genentech Inc Compositions and methods of using angiopoietin-like 4 protein
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CA2599967C (en) 2005-03-02 2014-10-21 Biogen Idec Ma Inc. Kim-1 antibodies for treatment of th2-mediated conditions
EP1871797A2 (de) * 2005-04-18 2008-01-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Toll-like receptor 14 (tlr 14) und anwendung davon
WO2007008647A2 (en) * 2005-07-07 2007-01-18 Vanderbilt University Diagnosing and grading gliomas using a proteomics approach
CN101415325A (zh) * 2005-11-29 2009-04-22 内华达肿瘤研究所 用于治疗和诊断与骨髓增生异常综合征(mds)相关的增殖性病症的sall4的靶向
AU2006321841C1 (en) 2005-12-08 2013-01-24 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to protein tyrosine kinase 7 ( PTK7 ) and their use
AR059432A1 (es) 2006-02-10 2008-04-09 Genentech Inc Anticuerpos anti-fgf19 y metodos que usan estos
NZ571068A (en) 2006-03-21 2012-06-29 Genentech Inc An antibody that can bind human alpha5beta1
US7723052B2 (en) 2006-05-11 2010-05-25 Quark Pharmaceuticals, Inc. Screening systems utilizing RTP801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
GB0620695D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Composition and methods for the treatment of nurdegenerative disease
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
EP1932854A1 (de) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lysosomal assoziiertes Membranprotein (LAMP) wie Polypeptide, Liganden dazu und Verwendung davon im Rahmen der Detektion und Reinigung menschlicher, plasmazytoider dendritischer Zellen
EP2377952A1 (de) * 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Verfahren zur Diagnostizierung und Behandlung von Astrozytoma
DK2567707T3 (en) * 2007-07-27 2017-07-31 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
CA2693852C (en) 2007-08-03 2016-11-29 Genentech, Inc. Humanized anti-fgf19 antagonists and methods using same
CA2736170A1 (en) 2007-09-06 2009-03-12 Case Western Reserve University Methods for diagnosing and treating cancers
CL2008002856A1 (es) 2007-09-26 2009-01-16 Genentech Inc Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1).
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CN102159248B (zh) 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
EP2326731B1 (de) * 2008-08-25 2013-11-13 Janssen Biotech, Inc. Biomarker zur anti-tnf-behandlung bei colitis ulcerosa und damit zusammenhängenden erkrankungen
WO2010047310A1 (ja) 2008-10-20 2010-04-29 大日本住友製薬株式会社 腫瘍抗原ペプチド及びその利用
AU2014201027B2 (en) * 2008-12-08 2015-11-19 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
CA2745492A1 (en) 2008-12-08 2010-06-17 Compugen Ltd. A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide
TWI504409B (zh) 2009-03-25 2015-10-21 Genentech Inc 新穎抗-α5β1抗體及其用途
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
HRP20211444T1 (hr) 2010-01-29 2021-12-24 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antitijelo
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
EP2662095A1 (de) 2010-04-15 2013-11-13 Spirogen Sàrl Pyrrolobenzodiazepine und Konjugate daraus
RU2755066C2 (ru) 2010-06-08 2021-09-13 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
PT2750713E (pt) 2011-10-14 2016-01-20 Genentech Inc Pirrolobenzodiazepinas e conjugados das mesmas
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
CN108530535B (zh) 2012-02-15 2021-02-26 诺和诺德股份有限公司 结合肽聚糖识别蛋白1的抗体
ES2640268T3 (es) 2012-02-15 2017-11-02 Novo Nordisk A/S Anticuerpos que se unen a y bloquean un receptor desencadenante expresado en células mieloides 1 (TREM-1)
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
RU2015106673A (ru) 2012-08-02 2016-09-20 Дженентек, Инк. Антитела к рецептору эндотелина типа в (etbr) и иммуноконъюгаты
WO2014022680A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
EP2906253B9 (de) 2012-10-12 2019-04-10 ADC Therapeutics SA Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
BR112015008174B1 (pt) 2012-10-12 2022-12-27 Medimmune Limited Conjugados de pirrolobenzodiazepina-anticorpo, composição farmacêutica compreendendo ditos conjugados e usos dos mesmos para tratar doença proliferativa e cancêr
NZ707490A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
DK2906296T3 (en) 2012-10-12 2018-05-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2906250B1 (de) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
BR112015014669B1 (pt) 2012-12-21 2023-09-26 Medimmune Limited Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
KR102066319B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
CN105307685B (zh) 2013-03-13 2019-03-08 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
EP3054986B1 (de) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepin-antikörper-konjugate
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
MX2016007578A (es) 2013-12-16 2016-10-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
EP3082874A2 (de) 2013-12-16 2016-10-26 Genentech, Inc. Peptidomimetische verbindungen und antikörper-wirkstoff-konjugate davon
FI3172232T3 (fi) 2014-07-17 2024-03-19 Novo Nordisk As TREM-1-vasta-aineiden kohdennettu mutageneesi viskositeetin alentamista varten
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン及びそのコンジュゲート
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック, インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
WO2016044560A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
BR112017011111A2 (pt) 2014-11-25 2017-12-26 Adc Therapeutics Sa conjugados de pirrolobenzodiazepina-anticorpo
MX2017007169A (es) 2014-12-03 2018-05-02 Genentech Inc Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017165734A1 (en) 2016-03-25 2017-09-28 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
WO2017214024A1 (en) 2016-06-06 2017-12-14 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
DK3612537T3 (da) 2017-04-18 2022-08-08 Medimmune Ltd Pyrrolobenzodiazepinkonjugater
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗cd19 adcを投与するための投与レジメ
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP2020534300A (ja) 2017-09-20 2020-11-26 ピーエイチ・ファーマ・カンパニー・リミテッドPh Pharma Co., Ltd. タイランスタチン類似体
US11667713B2 (en) 2017-12-28 2023-06-06 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
JOP20200240A1 (ar) 2018-04-02 2020-09-27 Bristol Myers Squibb Co أجسام مضادة ضد- trem-1 واستخداماتها
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
EP3870235A1 (de) 2018-10-24 2021-09-01 F. Hoffmann-La Roche AG Konjugierte chemische abbauauslöser und verwendungsverfahren
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP7085666B2 (ja) 2020-03-31 2022-06-16 中外製薬株式会社 Dll3標的多重特異性抗原結合分子およびその使用
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114113603B (zh) * 2021-06-30 2023-11-17 四川大学华西医院 Cytl1作为胃癌预后标志物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
AU1724000A (en) * 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRAWUNDER U ET AL: "Interferon-gamma arrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells.", EUROPEAN JOURNAL OF IMMUNOLOGY. FEB 1993, vol. 23, no. 2, February 1993 (1993-02-01), pages 544 - 551, XP009053201, ISSN: 0014-2980 *

Also Published As

Publication number Publication date
CA2459219A1 (en) 2003-03-27
WO2003025138A3 (en) 2003-05-08
WO2003025138A2 (en) 2003-03-27
JP2005518782A (ja) 2005-06-30
EP1434881A2 (de) 2004-07-07
AU2002330039A1 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
EP1434881A4 (de) Verfahren zur diagnose von krebszusammensetzungen und verfahren zum screening auf krebsmodulatoren
AU2002245317A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
EP1474528A4 (de) Methoden zur diagnose von prostatakrebs, zusammensetzungen und methoden zur untersuchung auf prostatakrebs-modulatoren
AU2002309583A1 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
AU2002347428A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
AU3491001A (en) Compositions and methods for the early diagnosis of ovarian cancer
AU3983201A (en) Compositions and methods for the early diagnosis of ovarian cancer
WO2002068677A8 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2002251844A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2002079492A8 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
PL349322A1 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
AU2002249871A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
EP1317669A4 (de) Diagnoseverfahren für kolorektalen krebs, zusammensetzung und verfahren zum schutz für kolorektale krebsmodulatoren
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
EP1476067A4 (de) Neue zusammensetzungen und verfahren gegen krebs
EP1509539A4 (de) Neue zusammensetzungen und verfahren gegen krebs
IL145397A0 (en) Compositions and methods for treatment of cancer
EP1349485A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose des ovarialkarzinoms
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040324

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060419